Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1645487 | 0.80 | SLC6A4 (0.64) | SLC6A4SLC6A2SLC6A3TDP1MAPT | |
| SCHEMBL1644437 | 0.80 | SLC6A4 (0.64) | SLC6A4SLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL1645176 | 0.80 | SLC6A4 (0.65) | SLC6A4SLC6A2SLC6A3TDP1MAPT | |
| SCHEMBL5833101 | 0.79 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL236212 | 0.79 | SLC6A4 (0.64) | SLC6A4SLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL1644221 | 0.79 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL1645157 | 0.77 | SLC6A4 (0.64) | SLC6A4SLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL1644194 | 0.77 | SLC6A4 (0.65) | SLC6A4SLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL1644432 | 0.76 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3TDP1MAPT | |
| SCHEMBL1645804 | 0.76 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004404-A1 | RADIOLABELLING METHODS | HAMMERSMITH IMANET LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004404-A1 | RADIOLABELLING METHODS | ARFGEF1, TMEM14C, PIGO | SLC6A4 766/4885SLC6A2 274/4885SLC6A3 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.